Birth rates similar for ART, natural conception
July 13th 2012Not only do live-birth rates with assisted reproductive technology (ART) approach those with spontaneous conception, but success rates do not diminish with advancing maternal age if donor oocytes are used. So says an analysis of data on more than 250,000 women.
Read More
U/S study shows impact of prenatal SSRIs, maternal depression
July 13th 2012Use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy is associated with smaller fetal head circumference-a prenatal marker of brain volume-and with higher risk of preterm birth (< 37 weeks), according to findings from a prospective population-based study from the Netherlands.
Read More
Contraceptive implants OK for overweight/obese women
July 6th 2012The etonogestrel subdermal contraceptive implant is just as effective in overweight and obese women as it is in women of normal weight and is as effective as an intrauterine device (IUD) (either the levonorgestrel intrauterine system or copper T380A), according to a recent study in Obstetrics and Gynecology.
Read More
FDA approves new treatment for HER2-positive late-stage breast Cancer
June 29th 2012The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read More
FDA finds no major safety issues for compounded 17P
June 29th 2012Analysis by the United States Food and Drug Administration (FDA) of compounded 17α-hydroxyprogesterone caproate (17P) shows the samples meet the potency and total purity standards for Makena, the branded version of the drug. Testing was done on 16 samples of bulk 17P active pharmaceutical ingredients (API) in response to questions from K-V Pharmaceuticals, Makena’s sponsor, about potency and purity of the compounded product.
Read More
New U/S-based tool for prediction of fetal weight and adverse outcomes
June 21st 2012Customized estimated fetal weight (EFW) percentiles based on ultrasound (U/S)-derived EFWs better predict adverse perinatal outcomes than older population-based methods, according to an historic cohort study.
Read More
VBAC or no VBAC? That is the ongoing question
June 7th 2012Shared perception of the safety of a trial of labor after cesarean delivery among all participants appears to be the deciding factor in whether that option is offered, concludes a report by the Agency for Healthcare Research and Quality.
Read More
History of fast labor may preclude elective induction
June 1st 2012Women who undergo elective induction of labor for a history of fast labor continue the trend of delivering in about half the time of other women, but the benefit of induction is small, a study from the Summa Health System reports.
Read More
LARCs have advantage in preventing teen pregnancy
June 1st 2012Long-acting reversible contraceptives (LARCs) are significantly more effective than oral contraceptive pills, rings, or patches in preventing unintended pregnancy in adolescent girls and young women, a large prospective cohort study from Washington University School of Medicine reports.
Read More
Ob/gyns should screen for CVD, cardiologists advise
June 1st 2012According to a study presented at the 2012 Annual Meeting of the Society for Cardiovascular Angiography and Interventions, many women are unaware of their risk for cardiovascular disease (CV), but a screening tool completed during their annual ob/gyn examination could change that.
Read More
Ovarian Ca: Predictive tool for outcomes promising
June 1st 2012A new algorithm based on gene expression data for 151 DNA repair genes can identify outcomes and response to platinum-based chemotherapy in patients with epithelial ovarian cancer, researchers at the Dana-Farber Cancer Institute report.
Read More